Analysts Offer Predictions for JSPR FY2029 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Jasper Therapeutics in a report issued on Wednesday, January 8th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($10.81) per share for the year. HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

JSPR has been the topic of a number of other reports. JMP Securities restated a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a research report on Monday, January 6th. BMO Capital Markets assumed coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target on the stock. Finally, Royal Bank of Canada cut their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $67.75.

Jasper Therapeutics Stock Performance

JSPR opened at $7.05 on Friday. The company has a fifty day moving average of $21.37 and a two-hundred day moving average of $20.27. The stock has a market capitalization of $105.76 million, a price-to-earnings ratio of -1.49 and a beta of 2.18. Jasper Therapeutics has a fifty-two week low of $6.57 and a fifty-two week high of $31.01.

Institutional Trading of Jasper Therapeutics

A number of institutional investors have recently made changes to their positions in JSPR. Braidwell LP purchased a new position in Jasper Therapeutics in the 3rd quarter valued at $9,091,000. Ally Bridge Group NY LLC grew its stake in Jasper Therapeutics by 82.7% during the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after acquiring an additional 180,852 shares in the last quarter. Samsara BioCapital LLC raised its holdings in Jasper Therapeutics by 11.4% in the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after acquiring an additional 59,642 shares during the last quarter. FMR LLC acquired a new position in shares of Jasper Therapeutics during the 3rd quarter worth approximately $722,000. Finally, Bank of New York Mellon Corp purchased a new position in Jasper Therapeutics during the second quarter worth approximately $740,000. 79.85% of the stock is owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.